Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 2586422)

Published in Bioorg Med Chem on August 27, 2008

Authors

Yongcheng Song1, Julian M W Chan, Zev Tovian, Aaron Secrest, Eva Nagy, Kilannin Krysiak, Kyle Bergan, Michael A Parniak, Eric Oldfield

Author Affiliations

1: Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801, USA.

Articles cited by this

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A (1992) 5.19

A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci U S A (1992) 4.61

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell (1999) 3.67

Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem (1994) 3.60

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A (1998) 3.31

Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol (2001) 2.95

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73

Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem (2002) 2.14

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol (1996) 2.03

A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92

An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine. J Virol (1996) 1.74

Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des (1993) 1.69

Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. J Am Chem Soc (2006) 1.48

3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem (2003) 1.35

Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr Purif (1996) 1.25

Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone (1987) 1.12

Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem (2005) 1.12

3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase. Biochemistry (2007) 0.99

Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase. J Med Chem (2005) 0.95

Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem (2006) 0.93

Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate. J Biol Chem (2006) 0.92

A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer. Biochem J (2007) 0.82

Articles by these authors

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02

An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. J Med Chem (2002) 3.82

A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science (2008) 2.96

Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem (2006) 2.93

Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol (2008) 2.88

Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem (2004) 2.41

Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A (2007) 2.00

Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem (2006) 1.98

An NMR investigation of CO tolerance in a Pt/Ru fuel cell catalyst. J Am Chem Soc (2002) 1.94

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol (2012) 1.87

HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol (2006) 1.83

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother (2002) 1.82

Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc (2009) 1.75

Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res (2005) 1.75

Antibacterial drug leads targeting isoprenoid biosynthesis. Proc Natl Acad Sci U S A (2012) 1.69

Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. J Am Chem Soc (2008) 1.57

Bioorganometallic mechanism of action, and inhibition, of IspH. Proc Natl Acad Sci U S A (2010) 1.54

Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. J Am Chem Soc (2006) 1.48

Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins (2006) 1.47

Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem (2009) 1.45

Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res (2011) 1.44

A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 1.43

Diterpene cyclases and the nature of the isoprene fold. Proteins (2010) 1.41

3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem (2003) 1.35

Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J Biol Chem (2003) 1.31

The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem (2005) 1.30

Harmonising evidence-based medicine teaching: a study of the outcomes of e-learning in five European countries. BMC Med Educ (2008) 1.30

Carbon-13 NMR shielding in the twenty common amino acids: comparisons with experimental results in proteins. J Am Chem Soc (2002) 1.29

First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol (2012) 1.28

Organometallic mechanism of action and inhibition of the 4Fe-4S isoprenoid biosynthesis protein GcpE (IspG). Proc Natl Acad Sci U S A (2010) 1.28

Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J Virol (2005) 1.26

Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry (2005) 1.25

Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem (2014) 1.24

Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase. J Am Chem Soc (2006) 1.22

The effectiveness of a clinically integrated e-learning course in evidence-based medicine: a cluster randomised controlled trial. BMC Med Educ (2009) 1.22

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem (2002) 1.22

Phylogenetic analysis reveals extensive evolution of avian paramyxovirus type 1 strains of pigeons (Columba livia) and suggests multiple species transmission. Virus Res (2003) 1.21

(57)Fe Mössbauer isomer shifts of heme protein model systems: electronic structure calculations. J Am Chem Soc (2002) 1.21

Effectiveness of an e-learning course in evidence-based medicine for foundation (internship) training. J R Soc Med (2010) 1.21

Inhibition of the Fe(4)S(4)-cluster-containing protein IspH (LytB): electron paramagnetic resonance, metallacycles, and mechanisms. J Am Chem Soc (2010) 1.21

Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. J Med Chem (2008) 1.21

A density functional theory investigation of Fe-N-O bonding in heme proteins and model systems. J Am Chem Soc (2003) 1.21

Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem (2004) 1.21

Thermodynamics of bisphosphonates binding to human bone: a two-site model. J Am Chem Soc (2009) 1.21

Photoaffinity antigens for human gammadelta T cells. J Immunol (2008) 1.19

The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog (2013) 1.18

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem (2008) 1.18

Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. AIDS Res Hum Retroviruses (2006) 1.17

Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem (2004) 1.16

The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem (2007) 1.16

Ultrahigh resolution protein structures using NMR chemical shift tensors. Proc Natl Acad Sci U S A (2011) 1.15

In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother (2002) 1.14

Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. Chem Biol Drug Des (2011) 1.13

Cytochrome P450: an investigation of the Mössbauer spectra of a reaction intermediate and an Fe(IV)[double bond]O model system. J Am Chem Soc (2004) 1.13

Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem (2005) 1.13

Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions. Ann Surg Oncol (2011) 1.12

Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem (2005) 1.12

Mechanism of action and inhibition of dehydrosqualene synthase. Proc Natl Acad Sci U S A (2010) 1.11

Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem (2002) 1.11

Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J Biol Chem (2001) 1.11

A solid state 13C NMR, crystallographic, and quantum chemical investigation of chemical shifts and hydrogen bonding in histidine dipeptides. J Am Chem Soc (2005) 1.10

The H(+)-pyrophosphatase of Rhodospirillum rubrum is predominantly located in polyphosphate-rich acidocalcisomes. J Biol Chem (2004) 1.10

Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis (2002) 1.10

Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents (2004) 1.10

Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin. J Med Chem (2006) 1.09

Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity. Proc Natl Acad Sci U S A (2012) 1.09

Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int J Biochem Cell Biol (2004) 1.09

NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. J Am Chem Soc (2008) 1.09

On the Mössbauer spectra of isopenicillin N synthase and a model (FeNO)7 (S = 3/2) system. J Am Chem Soc (2004) 1.08

Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth. Antimicrob Agents Chemother (2010) 1.07

Avian influenza virus H13 circulating in ring-billed gulls (Larus delawarensis) in southern Ontario, Canada. Avian Dis (2010) 1.05

Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem Biol Drug Des (2010) 1.04

Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Biology (Basel) (2012) 1.03

Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators. Angew Chem Int Ed Engl (2010) 1.03

Mössbauer quadrupole splittings and electronic structure in heme proteins and model systems: a density functional theory investigation. J Am Chem Soc (2002) 1.03

Are free radicals involved in IspH catalysis? An EPR and crystallographic investigation. J Am Chem Soc (2012) 1.02

Farnesyl diphosphate synthase inhibitors from in silico screening. Chem Biol Drug Des (2013) 1.02

Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob Agents Chemother (2012) 1.01

Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol (2002) 1.01

Protein structure refinement using 13C alpha chemical shift tensors. J Am Chem Soc (2009) 1.01

Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother (2012) 1.01

Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents (2004) 1.00

3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase. Biochemistry (2007) 0.99

Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses (2002) 0.99

Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2'F-ANA constructs containing acyclic nucleotide inserts. J Am Chem Soc (2003) 0.99

Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem (2009) 0.99

Biochemical mechanism of HIV-1 resistance to rilpivirine. J Biol Chem (2012) 0.99

Magic-angle spinning (31)P NMR spectroscopy of condensed phosphates in parasitic protozoa: visualizing the invisible. FEBS Lett (2002) 0.98

Pyridine inhibitor binding to the 4Fe-4S protein A. aeolicus IspH (LytB): a HYSCORE Investigation. J Am Chem Soc (2011) 0.98

Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol (2011) 0.97

Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase complexes. J Am Chem Soc (2004) 0.97

Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase. J Med Chem (2005) 0.95